MARKET

KOD

KOD

Kodiak Sciences Inc.
NASDAQ
27.96
+0.01
+0.04%
After Hours: 28.10 +0.14 +0.50% 18:11 12/31 EST
OPEN
27.67
PREV CLOSE
27.95
HIGH
29.04
LOW
27.51
VOLUME
1.58M
TURNOVER
--
52 WEEK HIGH
31.18
52 WEEK LOW
1.920
MARKET CAP
1.71B
P/E (TTM)
-6.7882
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at KOD last week (1222-1226)?
Weekly Report · 12/29/2025 10:06
Dynavax Technologies, Omeros, Agios Pharmaceuticals, Nike And Other Big Stocks Moving Higher On Wednesday
Benzinga · 12/24/2025 16:06
U.S. RESEARCH ROUNDUP-APi Group, Elf Beauty, Tesla
Reuters · 12/23/2025 07:05
KODIAK SCIENCES INC <KOD.O>: JEFFERIES RAISES TARGET PRICE TO $39 FROM $24
Reuters · 12/23/2025 04:57
Weekly Report: what happened at KOD last week (1215-1219)?
Weekly Report · 12/22/2025 10:06
Friday's After-Hours Gainers: Biotech And Genomics Stocks Show Strength
NASDAQ · 12/22/2025 04:20
Major Insider Move Signals Bold Confidence in Kodiak Sciences Stock
TipRanks · 12/20/2025 02:05
Felix J. Baker, Director, Reports Acquisition of Kodiak Sciences Inc. Common Shares
Reuters · 12/19/2025 21:07
More
About KOD
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab tedromer, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy and wet age-related macular degeneration. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate designed to inhibit interleukin-6 (IL-6)-mediated inflammation and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.

Webull offers Kodiak Sciences Inc stock information, including NASDAQ: KOD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KOD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KOD stock methods without spending real money on the virtual paper trading platform.